Next Article in Journal
Efficacy of Nondiuretic Pharmacotherapy for Improving the Treatment of Congestion in Patients with Acute Heart Failure: A Systematic Review of Randomised Controlled Trials
Previous Article in Journal
An sEMG-Controlled Forearm Bracelet for Assessing and Training Manual Dexterity in Rehabilitation: A Systematic Review
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Heart Failure with Reduced Ejection Fraction and Prognostic Scales: The Impact of Exercise Modality in Cardiopulmonary Exercise Tests

by
Julia Herrero Huertas
1,
Marta García Clemente
2,*,
Beatriz Díaz Molina
3,
José Luis Lambert Rodríguez
3 and
Marta Íscar Urrutia
2
1
Department of Pneumology, Fundación Jiménez Díaz University Hospital, 28040 Madrid, Spain
2
Department of Pneumology, Asturias Central University Hospital, 33011 Oviedo, Spain
3
Department of Cardiology, Asturias Central University Hospital, 33011 Oviedo, Spain
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2022, 11(11), 3122; https://doi.org/10.3390/jcm11113122
Submission received: 19 May 2022 / Revised: 28 May 2022 / Accepted: 30 May 2022 / Published: 31 May 2022
(This article belongs to the Section Cardiology)

Abstract

:
The cardiopulmonary exercise (CPET) test is an essential tool to determine the severity, prognosis, and need for invasive treatments in heart failure with reduced ejection fraction (HFrEF) but disregards the exercise modality. The present study aimed at analyzing the differences between treadmill and cycle-ergometer exercises. This was a prospective study, involving 65 patients with HfrEF who performed treadmill exercise followed by cycle-ergometer exercise 72 h later. We enrolled 65 patients, aged 58 ± 9 years, with an ejection fraction of 29 ± 9%. Peak VO2 was 20% greater (95% CI: 18–21%; p < 0.000) on the treadmill, and the ventilatory efficiency estimated by the VE/VCO2 slope (32 ± 8 vs. 34 ± 9; p < 0.05). The ventilatory response was greater on the treadmill: maximum ventilation (55 ± 16 vs. 46 ± 11 L/min; p < 0.000) and ventilatory reserve at the maximum effort (28 ± 17 vs. 41 ± 15%; p < 0.000). These values led to a change in the functional class of 23 (51%) patients and ventilatory class of 28 (47%) patients. Differences in the main parameters, including peak VO2 and VE/VCO2, impact prognostic scales and possible advanced treatments; therefore, the results should be interpreted in accordance with the exercise modality.

1. Introduction

Exercise intolerance in heart failure with reduced ejection fraction (HFrEF) results from changes in oxygen delivery to skeletal muscles and its utilization by myocytes [1]. Cardiopulmonary exercise tests (CPETs) demonstrate this imbalance between oxygen supply and demand, particularly decreased oxygen consumption (VO2) and maximum workload [2].
CPET is an objective, reproducible and non-invasive test [3] for the functional capacity of patients with HFrEF, routinely used in the baseline and follow-up assessments of this disease to determine its severity, prognosis and need for invasive treatments [4]. The gold-standard quantifier of functional capacity in CPET is VO2 [5].
The most common exercise modalities in CPET are the treadmill and cycle ergometer, but protocols vary with the objective and limitation and/or weakness of the subject being studied [6,7]. Advantages of the treadmill stress test are familiarity with the exercise modality, participation of a higher number of muscle groups and greater work against gravity, thereby increasing the stress to which the systems involved in response to exercise are subjected [7,8]. For all these factors, peak VO2 is 5–16% higher with treadmill than with cycle ergometer tests [9,10,11]. This difference in peak VO2 may occur in diseases whose prognostic stratification is based on this parameter, among other factors [2]. Disadvantages of the treadmill are determined by difficulties in the exact quantification of the work to which the patient has been subjected and relationship between the speed–slope and the metabolic cost [7]. The other CPET modality, the cycle ergometer, minimizes artifacts, is more affordable, and requires less space compared to the treadmill, but its main advantage is to facilitate quantification of the external work to which the patient is subjected [7]. Conversely, the cycle ergometer leads to lower-limb fatigue in untrained participants and lower VO2 compared to the treadmill, among other disadvantages [12].
The analysis of peak VO2 for determining prognostic scale scores [13] and decision making regarding the indication of advanced therapies, such as heart transplantation [14] or left ventricular assist devices (LVADs) [4,15], disregards the exercise modality, assuming that the oxygen requirement is identical in both tests. This assumption can lead to error by underestimating the real functional class of the patient.
Recently, parameters in addition to peak VO2 have been incorporated into the prognostic stratification of HFrEF, such as the VE/VCO2 slope [16] and exercise oscillatory ventilation [17] (EOV). These parameters have become increasingly relevant for obtaining predictive information, regardless of the patient’s effort.
To date, few studies involving a small sample size of select patients have compared the results from both exercise modalities using the parameters peak VO2 and VE/VCO2 slope [18,19,20,21,22,23,24].
The aim of the present study was to analyze differences in CPET parameters between exercise modalities (treadmill and cycle ergometer) and their impact on the functional assessment and severity stratification of patients with HFrEF.

2. Materials and Methods

We prospectively enrolled outpatients with heart failure from the Asturias Central University Hospital (Hospital Universitario Central de Asturias—HUCA). All of them were in a clinically stable condition, undergoing current optimal treatment, and were referred for CPET from July 2019 to March 2020.
Inclusion criteria were left ventricular ejection fraction (LVEF) < 40% and New York Heart Association functional classes I–III [25]. Exclusion criteria included: (a) hospitalization within the last 3 months for decompensated heart disease or uncontrolled atrial fibrillation, (b) patients suffering any severe event during the CPETs or the cooldown period as myocardial ischemia and/or severe arrhythmia (ventricular tachycardia and ventricular fibrillation), and (c) not having completed both CPETs.
Demographic, anthropometric, comorbidity, and treatment data for all patients included in the study were recorded.
The study protocol was approved by the Research Ethics Committee of the Principality of Asturias (registration number 174/19). All patients included in the study received a patient information sheet and signed the informed consent form for participation in the study.

2.1. CPET

Each patient performed two CPETs up to their maximum tolerance. The first CPET was performed on a treadmill (HP Cosmos Pulsar 2002, Nußdorf, Germany), using a modified version of the protocol developed by Bruce [26], comprising 1 min stages with increasing speeds ranging from 2.7 to 6 km/h and progressive incline from 0% to 16%. The second CPET was performed 72 h later on a cycle ergometer (Corival Lode BV, Groninga, Netherlands) with 5–20 W/min increments adjusted to the functional limitation of each patient. Before the second test, the patients were evaluated to ensure the absence of changes in symptoms, physical findings, weight, and medication.
In addition to performing the breath-by-breath gas analysis (Ergocard, Medisoft Exp’Air 1.25, Breeze, Belgium) averaging the data every 10 s, the oxygen saturation and heart rate (HR) were continuously monitored by pulse oximetry and 12-lead electrocardiography, respectively. Every 2 min, blood pressure (BP) was manually recorded, and degrees of dyspnea and lower-limb fatigue were assessed using the modified Borg scale (0–10) [27]. The ergospirometer was calibrated before each test [12].
HR (bpm), oxygen saturation (%), VO2 (mL/min), CO2 production (VCO2; mL/min) and minute ventilation (VE; L/min) were recorded continuously. The following values were calculated: respiratory quotient (RQ), ventilatory equivalents for O2 and CO2 (EqO2 and EqCO2), VE/VCO2 slope, ventilatory threshold (VT) using the system of ventilatory equivalents [6], breathing reserve (BR = (1 − [VE/maximal voluntary ventilation]) × 100) [6], end-tidal CO2 and O2 pressures (PetCO2 and PetO2; mmHg), O2 pulse (VO2/HR; mL/bpm), and the presence of EOV, which was measured as cyclic oscillations in ventilation during ≥60% of exercise with an amplitude ≥15% of the mean value at rest [6]. Maximum values were recorded as those averaged over the last 20 s of the test. The HR recovery index (HRR-1; bpm) calculated the difference between the maximum HR during exercise and the HR 1 min after completing the test [28].
The criteria used to end the test were the maximum effort perceived by the supervised patient, serious cardiovascular events, and presence of limiting symptoms. In the recovery phase, monitoring was maintained for 3 min [6].
Functional limitation was rated using the Weber classification [29]. This classification divides patients with HFrEF as functions of the peak VO2/kg and prognosis: class A, peak VO2/kg ≥ 20 min/mL/kg; class B, peak VO2/kg = 16–20 min/mL/kg; class C, peak VO2/kg = 10–15 min/mL/kg; and class D, peak VO2/kg ≤ 10 min/mL/kg. Patients in class A have the best prognosis.
The ventilatory classification was proposed by Arena et al. [30], which divides patients into four classes as functions of the VE/VCO2 slope and prognosis: class I, VE/VCO2 slope < 30; class II, ≥30 VE/VCO2 slope < 36; class III, ≥36 VE/VCO2 slope < 45; and class IV, VE/VCO2 slope ≥ 45. Patients with ventilatory class I have the best prognosis.

2.2. Spirometry

Prior to CPET, spirometry was performed in a seated position to record the forced expiratory volume in the first second (FEV1), the forced vital capacity (FVC), and FEV1/FVC ratio. These parameters were interpreted using the theoretical reference values of the Global Lung Initiative [31]. Obstruction was defined as having a post-bronchodilator FEV1/FVC ratio lower than the lower limit of normal (LLN) [32]. The diagnosis of chronic obstructive pulmonary disease (COPD) was conducted following the criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [33]. Maximal voluntary ventilation (MVV) was estimated using the formula FEV1 × 40 [6].

2.3. Statistical Analysis

Data analysis was conducted using the statistical program Stata (Version 15.4.2, StataCorp, College Station, TX, USA). A descriptive analysis was initially performed. Numerical data are expressed as numbers and percentages. The quantitative variables are expressed as the mean and standard deviation. The paired t-test was used to compare continuous data. Differences between proportions were analyzed using the Pearson chi-squared test. Correlations between peak VO2 in each exercise modality were evaluated by calculating the Pearson correlation. A p-value of ≤0.05 was considered as statistically significant.

3. Results

From the 80 patients initially referred for the study, 15 were excluded; 10 did not fulfill the inclusion criteria and the other 5 did not complete the two CPETs previously described. Finally, we enrolled a total of 65 patients, including 49 (75%) men and 16 (25%) women, with a mean age of 57.8 ± 9.3 years. The mean LVEF was 29.5% ± 8.6%. Table 1 outlines the characteristics of the participants.
Comorbidities included atrial fibrillation with controlled ventricular response in 12 (18%) patients and COPD in 18 (28%) patients. COPD was mild and moderate in 44% and 50% of the patients, respectively.

3.1. CPET

The time interval between the two CPETs was 3.0 ± 1.9 days. Table 2 shows the detailed results of both CPETs.

3.2. Effort Level

The exercise duration and maximum RQ were similar in both exercise modalities. RQ reached 1.04 ± 0.05 and 1.03 ± 0.06 with the treadmill and cycle ergometer, respectively (p = 0.43), without significant differences, suggesting a similar degree of effort.
The treadmill exercise was suspended by four (6%) patients, because of dyspnea in two patients and hypertensive crisis in the other two patients. The cycle ergometer test was suspended by 15 (23%) patients because of lower-limb fatigue in five (33%) patients, hypertensive crisis in three (20%) patients, dyspnea in three (20%) patients, and other reasons in four (27%) patients.

3.3. VO2

Regarding variations in VO2 during CPET, baseline VO2 (subject at rest) did not differ significantly between the two modalities. However, VT and peak VO2 reached during exercise differed significantly between the two modalities (p < 0.000); Table 3; Figure 1.
The peak VO2/kg in treadmill and cycle ergometer exercises was 21.0 ± 5.1 and 16.9 ± 4.1 mL/min/kg, respectively, showing a significant difference (p < 0.000).
The peak VO2 and peak VO2/kg were 20% (95% confidence interval: 18–21%) higher value in the treadmill exercise than in the cycle ergometer exercise (p < 0.000). The correlation between peak VO2 and peak VO2/kg was excellent (r = 0.93 vs. 0.89, p < 0.000) in both ergometers.

3.4. Cardiovascular Response

The maximum HR was higher in the treadmill exercise than in the cycle ergometer exercise (117.3 ± 15.7 vs. 107.5 ± 15.2 bpm; p < 0.000), with a better HRR-1 (22.4 ± 12.8 vs. 16.4 ± 8.8 bpm; p < 0.000) in patients with a sinus rhythm (n = 53).
The O2 pulse (VO2/HR) in VT was 14.6 ± 3.6 and 12.5 ± 3.3 mL/bpm in the treadmill and cycle ergometer exercises, respectively, showing a significant difference (p < 0.000).
In the BP response throughout the test, systolic BP did not differ at the maximum exercise capacity, but diastolic BP at the maximum effort was significantly lower in the treadmill exercise than in the cycle ergometer exercise (81.5 ± 16.6 vs. 87.4 ± 16.2 mmHg; p < 0.000). In both tests, patients showed a hypertensive response to exercise, with systolic BP > 220 mmHg or diastolic BP > 120 mmHg in four patients (p = NS).
Figure 2 shows a comparison of the results of cardiovascular variables by ergometer.

3.5. Ventilatory Response and Gas Exchange

The ventilatory response was greater on the treadmill than on the cycle ergometer, at both the maximum respiratory rate (30.5 ± 5.6 vs. 27.3 ± 5.0 rpm; p < 0.000) and maximum VE (54.7 ± 16.3 vs. 45.8 ± 11.4 L/min; p < 0.000). Lower EqO2 (35.6 ± 4.9 vs. 37.0 ± 5.5; p < 0.05) and EqCO2 (36.3 ± 5.0 vs. 37.4 ± 5.4; p < 0.05), higher ΔPetCO2 (3.8 ± 4.0 vs. 2.3 ± 4.7; p < 0.05), and lower VE/VCO2 slope (32.2 ± 7.9 vs. 33.9 ± 8.8; p < 0.05) were also observed, reflecting a better ventilatory efficiency on the treadmill than on the cycle ergometer.
BR at the maximum effort was significantly lower on the treadmill than on the cycle ergometer (28.4 ± 17.1 vs. 41.1 ± 15.2%; p < 0.000).
Finally, EOV was present in 19 (30%) patients during the treadmill exercise and in 23 (36%) patients during the cycle ergometer exercise, with no significant differences (p = NS).
Figure 3 shows a comparison of the results of respiratory variables by ergometer.

3.6. Prognostic Classification

The Weber functional [29] and ventilatory [30] classifications were used for prognostic purposes. The Weber functional class varied as a function of peak VO2/kg. The ergometer showed a change in functional class in 36 (55%) participants, with a descent on the scale during the cycle ergometer exercise (Figure 4A).
The ventilatory class as a function of VE/VCO2 slope and ergometer changed in 31 (48%) patients, with 10 (15%) patients displaying a worse ventilatory efficiency on the treadmill and 21 (32%) on the cycle ergometer (Figure 4B).

3.7. Symptomatology and Preferences

The symptomatology of the patients according to the Borg questionnaire [27] throughout the test showed higher dyspnea values on the treadmill than on the cycle ergometer (5.4 ± 2.4 vs. 3.7 ± 2.3; p < 0.000) and higher lower-limb fatigue values on the cycle ergometer than on the treadmill (3.8 ± 3.1 vs. 4.8 ± 2.4; p < 0.05).
Regarding ergometer preference, 32 (50%) patients opted for the cycle ergometer, 26 (41%) opted for the treadmill, and six (9%) were indifferent to the type of ergometer (p = NS). The reasons for preferring the cycle ergometer were the greater sense of security and less dyspnea at the end of the test. The reason for preferring the treadmill was the greater familiarity with the type of exercise.

4. Discussion

The exercise modality in the CPET may affect the final VO2, changing the functional class and, accordingly, the therapeutic approach [13,34]. In our study, the peak VO2 and peak VO2/kg of patients with HFrEF were significantly higher when performing the CPET on the treadmill than on the cycle ergometer, with a 20% difference in both parameters, despite using protocols with a similar workload, as shown by no significant differences in RQ or test duration between the two ergometers.
The impact of this difference on VO2 was determined by prognostic scales [13,34], such as the Weber functional classification [29], as these functional classes changed in more than half of the patients, depending on the ergometer; and by current treatment guidelines for HFrEF because the most extended cutoff peak VO2/kg for considering the use of advanced therapies, such as LVAD or heart transplantation [4,14,15], is 12 mL/kg/min, without indicating the exercise modality of the CPET. In our study, peak VO2/kg was lower than 12 mL/kg/min in 1 (1.5%) patient on the treadmill and in 11 (17%) patients on the cycle ergometer. The same patient may show different values depending on the ergometer. Therapeutic recommendations are based on these values, irrespective of the ergometer used in the CPET.
The VE/VCO2 slope was lower, indicating a higher ventilatory efficiency when performing the test on the treadmill. In addition, the ventilatory class [30] changed in half of the patients as a function of the ergometer used in the CPET.
Regarding the ventilatory response, VE, RR, and BR reflected the higher ventilatory demand of the treadmill, although with a better ventilatory efficiency when analyzing PetCO2 and EqO2/EqCO2. Of these parameters, only PetCO2 had been studied in HFrEF by Mazaheri et al. [24], although in a small sample of exclusively male patients (n = 30) with significantly lower effort on the treadmill. These results highlight the importance of the exercise modality in ventilatory demand because the ventilatory response varies with the type of ergometer.
EOV may be a prognostic factor of HFrEF [13], in addition to VO2 and VE/VCO2 slope. However, no studies have assessed whether its presence varies as a function of exercise modality in HFrEF or not. In our study, the prevalence of EOV did not differ significantly, despite a non-significant tendency towards a higher prevalence with the cycle ergometer, which must be verified in future research.
The hemodynamic response in different exercise modalities was described by Kim et al. [20], in a study involving 18 patients with heart failure showing a higher cardiac output and a greater A–V difference in oxygen in treadmill tests as explanatory variables of the differences in VO2. In our study, the higher O2 pulse, as an indirect measure of the systolic volume and higher HR on the treadmill, corroborated the findings of Kim et al. [20] Using a higher number of muscle groups increases the metabolic requirement during exercise, and, consequently, the cardiac output and peak VO2. This phenomenon, together with the increase in catecholamines during the treadmill exercise and changes in blood flow distribution in HFrEF [20], may explain the higher HR on the treadmill and higher diastolic BP on the cycle ergometer. Regarding HRR-1, previous studies [22,23,24] reported disparate results. In our study, HRR-1 was better on the treadmill.
Finally, the patients’ preference for the ergometer did not differ significantly, but they felt more secure on the cycle ergometer and more familiar with the type of exercise on the treadmill.
A few studies compared the two ergometers in the 1990s [18,19,20], with a small sample size of select patients, as in Witte et al. [21] (n = 11), Maeder et al. [22] (n = 21), Beckers et al. [23] (n = 55) and Mazaheri et al. [24] (n = 30). VO2 differences ranged from 10% to 23% [18,19,20,21,22,23,24] and with considerable variability in VE/VCO2 slope [21,22,23,24]. These differences may be related to the characteristics of the selected patients, small sample size, and differences between protocols, in addition to the respiratory behavior and its repercussion on related parameters, such as BR, PetCO2, EqO2, EqCO2, and EOV. The patient’s preference for the exercise modality was also overlooked in those studies.
The strengths of the present study are its broader population sample than those published earlier and analysis of a higher number of parameters than those published in other studies, including ventilatory parameters, such as BR, EqO2, EqCO2, and the presence of EOV, which had not been previously compared in HFrEF. Similarly, another strength of this study was the level of effort achieved with both exercise modalities, which was similar. This study was limited by its single-center setting. Future multicenter studies should be performed to corroborate the results. The lack of randomization could be considered a limitation, although the symptoms, weight, or medication did not change when performing the CPET according to the usual practice of our center: first on a treadmill and after 72 h on a cycle ergometer. Finally, our sample represented as many patients treated in routine practice as possible and included patients with chronic obstructive pulmonary disease, which could serve as a reference for new studies performing subgroup analyses.

5. Conclusions

Treadmill exercise produces a higher peak VO2, with a higher ventilatory and cardiovascular response. In diseases whose prognostic classification partly depends on CPET parameters, such as HFrEF, the results of this test should be interpreted considering not only sex, age, disease, and comorbidity but also the ergometer used in the CPET.

Author Contributions

M.G.C. and M.Í.U. proposed the study, conducted the data collection and composed the manuscript; J.H.H. performed the statistical analysis, interpreted the results and composed the manuscript; B.D.M. and J.L.L.R. contributed expertly to the interpretation of the results and preparation of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Principality of Asturias (registration number 174/19).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Wasserman, J.; Hansen, D.; Sue, W.; Stringer, B.W. Principles of Exercise Testing and Interpretation, 4th ed; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2004. [Google Scholar]
  2. Corrà, U.; Piepoli, M.F.; Adamopoulos, S.; Agostoni, P.; Coats, A.J.; Conraads, V.; Ponikowski, P.P. Cardiopulmonary exercise testing in systolic heart failure in 2014: The evolving prognostic role A position paper from the committee on exercise physiology and training of the heart failure association of the ESC. Eur. J. Heart Fail. 2014, 1, 929–941. [Google Scholar] [CrossRef]
  3. Palange, P.; Ward, S.A.; Carlsen, K.H.; Carlsen, R.; Casaburi, C.G.; Gallagher, R.; Gosselink, D.E.; O’Donnell, L.; Puente-Maestu, A.M.; Schols, S.; et al. Recommendations on the use of exercise testing in clinical practice. Eur. Respir. J. 2007, 29, 185–209. [Google Scholar] [CrossRef]
  4. McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, H.; Čelutkienė, J.; Chioncel, O.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021, 42, 3599–3726. [Google Scholar] [CrossRef]
  5. Arena, R.; Myers, J.; Williams, M.A.; Gulati, M.; Kligfield, P.; Balady, G.J.; Collins, E.; Fletcher, G. Assessment of functional capacity in clinical and research settings: A scientific statement from the American Heart Association committee on exercise, rehabilitation, and prevention of the council on clinical cardiology and the council on cardiovascular n. Circulation 2007, 116, 329–343. [Google Scholar] [CrossRef]
  6. Balady, G.J.; Arena, R.; Sietsema, K.; Myers, J.; Coke, L.; Fletcher, G.F.; Forman, D.; Franklin, B.; Guazzi, M.; Gulati, M.; et al. Clinician’s guide to cardiopulmonary exercise testing in adults: A scientific statement from the American heart association. Circulation 2010, 12, 191–225. [Google Scholar] [CrossRef] [Green Version]
  7. Weisman, I.M.; Marciniuk, D.; Martinez, F.J.; Sciurba, F.; Sue, D.; Myers, J.; Casaburi, R.; Marciniuk, D.; Beck, K.; Zeballos, J.; et al. ATS/ACCP Statement on cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med. 2003, 16, 211–277. [Google Scholar] [CrossRef]
  8. Porszasz, J.; Stringer, W.C.R. Equipment, measurements and quality control. In Clinical Exercise Testing (ERS Monograph); Palange, P., Laveneziana, P., Neder, J.A., Eds.; European Respiratory Society: Sheffield, UK, 2018; pp. 59–81. [Google Scholar] [CrossRef]
  9. Hermansen, L.; Saltin, B. Oxygen uptake during maximal treadmill and bicycle exercise. J. Appl. Physiol. 1969, 26, 31–37. [Google Scholar] [CrossRef]
  10. Miyamara, M.; Honda, Y. Oxygen intake and cardiac output during maximal treadmill and bicycle exercise. J. Appl. Physiol. 1972, 32, 185–188. [Google Scholar] [CrossRef]
  11. Lockwood, P.; Yoder, J.; Deuster, P. Comparison and cross-validation of cycle ergometry estimates of VO2max. Med. Sci. Sport. Exerc. 1997, 29, 1513–1520. [Google Scholar] [CrossRef]
  12. Fletcher, G.F.; Balady, G.J.; Amsterdam, E.A.; Chaitman, B.; Eckel, R.; Fleg, J.; Froelicher, V.F.; Leon, A.S.; Pina, I.L.; Rodney, R.; et al. Exercise Standards for Testing and Training. Circulation 2001, 104, 1694–1740. [Google Scholar] [CrossRef] [Green Version]
  13. Malhotra, R.; Bakken, K.; D’Elia, E.; Lewis, G.D. Cardiopulmonary Exercise Testing in Heart Failure. JACC Heart Fail. 2016, 4, 607–616. [Google Scholar] [CrossRef]
  14. Truby, L.K.; Rogers, J.G. Advanced Heart Failure: Epidemiology, Diagnosis, and Therapeutic Approaches. JACC Heart Fail. 2020, 8, 523–536. [Google Scholar] [CrossRef]
  15. Potapov, E.V.; Antonides, C.; Crespo-Leiro, M.G.; Combes, A.; Färber, G.; Hannan, M.M.; Kukucka, M.; De Jonge, N.; Loforte, A.; Lund, L.H.; et al. 2019 EACTS Expert Consensus on long-term mechanical circulatory support. Eur. J. Cardio-Thorac. Surg. 2019, 56, 230–270. [Google Scholar] [CrossRef]
  16. Arena, R.; Myers, J.; Aslam, S.S.; Varughese, E.B.; Peberdy, M.A. Peak VO2 and VE/VCO2 slope in patients with heart failure: A prognostic comparison. Am. Heart J. 2004, 147, 354–360. [Google Scholar] [CrossRef]
  17. Cornelis, J.; Taeymans, J.; Hens, W.; Beckers, P.; Vrints, C.; Vissers, D. Prognostic respiratory parameters in heart failure patients with and without exercise oscillatory ventilation-A systematic review and descriptive meta-analysis. Int. J. Cardiol. 2015, 182, 476486. [Google Scholar] [CrossRef]
  18. Riley, M.; Northridge, D.B.; Henderson, E.; Stanford, C.F.; Nicholls, D.P.; Dargie, H.J. The use of an exponential protocol for bicycle and treadmill exercise testing in patients with chronic cardiac failure. Eur. Heart J. 1992, 13, 1363–1367. [Google Scholar] [CrossRef]
  19. Page, E.; Cohen-Solal, A.; Jondeau, G.; Douard, H.; Roul, G.; Kantelip, J.P.; Bussiere, J.L. Comparison of treadmill and bicycle exercise in patients with chronic heart failure. Chest 1994, 106, 1002–1006. [Google Scholar] [CrossRef]
  20. Kim, S.; Yamabe, H.; Yokoyama, M. Hemodynamic characteristics during treadmill and bicycle exercise in chronic heart failure: Mechanism for different responses of peak oxygen uptake. Jpn. Circ. J. 1999, 63, 965–970. [Google Scholar] [CrossRef] [Green Version]
  21. Witte, K.K.A.; Clark, A.L. Cycle exercise causes a lower ventilatory response to exercise in chronic heart failure. Heart 2005, 91, 225–226. [Google Scholar] [CrossRef] [Green Version]
  22. Maeder, M.T.; Wolber, T.; Ammann, P.; Myers, J.; Brunner-La Rocca, H.P.; Hack, D.; Riesen, W.; Rickli, H. Cardiopulmonary exercise testing in mild heart failure: Impact of the mode of exercise on established prognostic predictors. Cardiology 2008, 110, 135–141. [Google Scholar] [CrossRef] [Green Version]
  23. Beckers, P.J.; Possemiers, N.M.; Van Craenenbroeck, E.M.; Van Berendoncks, A.M.; Wuyts, K.; Vrints, C.J.; Conraads, V.M. Impact of exercise testing mode on exercise parameters in patients with chronic heart failure. Eur. J. Prev. Cardiol. 2012, 19, 389–395. [Google Scholar] [CrossRef]
  24. Mazaheri, R.; Sadeghian, M.; Nazarieh, M.; Niederseer, D.; Schmied, C. Performance of heart failure patients with severely reduced ejection fraction during cardiopulmonary exercise testing on treadmill and cycle ergometer; similarities and differences. Int. J. Environ. Res. Public Health 2021, 18, 12958. [Google Scholar] [CrossRef]
  25. Maddox, T.M.; Januzzi, J.L.; Allen, L.A.; Breathett, K.; Butler, J.; Davis, L.L.; Fonarow, G.C.; Ibrahim, N.E.; Lindenfeld, J.; Masoudi, F.A.; et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversig. J. Am. Coll. Cardiol. 2021, 77, 772–810. [Google Scholar] [CrossRef]
  26. Pereiro Alonso, M.E. Capacidad Aeróbica en una Población Adulta Sana y Calidad de Vida Relacionada con la salud. December. 2003. Available online: http://hdl.handle.net/10651/16219 (accessed on 17 October 2021).
  27. Wilson, R.C.; Jones, P.W. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin. Sci. 1989, 76, 277–282. [Google Scholar] [CrossRef] [Green Version]
  28. Nanas, S.; Anastasiou-Nana, M.; Dimopoulos, S.; Sakellariou, D.; Alexopoulos, G.; Kapsimalakou, S.; Papazoglou, P.; Tsolakis, E.; Papazachou, O.; Roussos, C.; et al. Early heart rate recovery after exercise predicts mortality in patients with chronic heart failure. Int. J. Cardiol. 2006, 110, 393–400. [Google Scholar] [CrossRef]
  29. Weber, K.T.; Kinasewitz, G.T.; Janicki, J.S.; Fishman, A.P. Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. Circulation 1982, 65, 1213–1223. [Google Scholar] [CrossRef] [Green Version]
  30. Arena, R.; Myers, J.; Abella, J.; Peberdy, M.A.; Bensimhon, D.; Chase, P.; Guazzi, M. Development of a ventilatory classification system in patients with heart failure. Circulation 2007, 115, 2410–2417. [Google Scholar] [CrossRef] [Green Version]
  31. Quanjer, P.H.; Stanojevic, S.; Cole, T.J.; Baur, X.; Hall, G.L.; Culver, B.H.; Enright, P.L.; Hankinson, J.L.; Ip, M.S.M.; Zheng, J.; et al. Multi-Ethnic Reference Values for Spirometry for the 3-95-Yr Age Range: The Global Lung Function 2012 Equations. Eur. Respir. J. 2012, 40, 1324–1343. [Google Scholar] [CrossRef]
  32. Fragoso, C.A.V.; Magnussen, H.; Miller, M.R.; Brusasco, V. The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of the FEV1/FVC Ratio. Ann. Am. Thorac. Soc. 2018, 15, 766–767. [Google Scholar] [CrossRef]
  33. Singh, D.; Agusti, A.; Anzueto, A.; Barnes, P.J.; Bourbeau, J.; Celli, B.R.; Criner, G.J.; Frith, P.; Halpin, D.M.G.; Han, M.; et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The GOLD Science Committee Report 2019. Eur. Respir. J. 2019, 53, 1900164. [Google Scholar] [CrossRef]
  34. Myers, J.; Arena, R.; Dewey, F.; Bensimhon, D.; Abella, J.; Hsu, L.; Chase, P.; Guazzi, M.; Peberdy, M.A. A cardiopulmonary exercise testing score for predicting outcomes in patients with heart failure. Am. Heart J. 2008, 156, 1177–1183. [Google Scholar] [CrossRef]
Figure 1. VO2 variation during CPET.
Figure 1. VO2 variation during CPET.
Jcm 11 03122 g001
Figure 2. Boxplot of cardiovascular variables and VO2 on the treadmill and cycle ergometer. (A) Peak VO2 (mL/min), (B) peak VO2/kg (mL/min/kg), (C) VO2/HR at VT (mL/bpm), (D) maximum HR (bpm), (E) HRR-1 (bpm), (F) systolic and diastolic BP at the maximum exercise (mmHg). VO2: oxygen consumption; HR: heart rate; HRR-1: HR recovery index; BP: blood pressure; NS: not significant.
Figure 2. Boxplot of cardiovascular variables and VO2 on the treadmill and cycle ergometer. (A) Peak VO2 (mL/min), (B) peak VO2/kg (mL/min/kg), (C) VO2/HR at VT (mL/bpm), (D) maximum HR (bpm), (E) HRR-1 (bpm), (F) systolic and diastolic BP at the maximum exercise (mmHg). VO2: oxygen consumption; HR: heart rate; HRR-1: HR recovery index; BP: blood pressure; NS: not significant.
Jcm 11 03122 g002
Figure 3. Boxplot of respiratory variables on the treadmill and cycle ergometer. (A) VE/VCO2 Slope, (B) maximum RR (rpm), (C) maximum VE (L/min), (D) VT Eq O2, (E) VT Eq CO2, (F) BR at maximum effort (%), (G) VT PET CO2 (mmHg). RR: respiratory rate; VE: ventilation; VT: ventilatory threshold; EqO2: oxygen equivalent; EqCO2: carbon dioxide equivalent; BR: breathing reserve; PETCO2: partial pressure end-tidal carbon dioxide; NS: not significant.
Figure 3. Boxplot of respiratory variables on the treadmill and cycle ergometer. (A) VE/VCO2 Slope, (B) maximum RR (rpm), (C) maximum VE (L/min), (D) VT Eq O2, (E) VT Eq CO2, (F) BR at maximum effort (%), (G) VT PET CO2 (mmHg). RR: respiratory rate; VE: ventilation; VT: ventilatory threshold; EqO2: oxygen equivalent; EqCO2: carbon dioxide equivalent; BR: breathing reserve; PETCO2: partial pressure end-tidal carbon dioxide; NS: not significant.
Jcm 11 03122 g003
Figure 4. (A) Analysis of the Weber functional class as a function of peak VO2/kg and ergometer. (B) Ventilatory class according to VE/VCO2 slope and ergometer.
Figure 4. (A) Analysis of the Weber functional class as a function of peak VO2/kg and ergometer. (B) Ventilatory class according to VE/VCO2 slope and ergometer.
Jcm 11 03122 g004
Table 1. Baseline characteristics of the included patients (n = 65).
Table 1. Baseline characteristics of the included patients (n = 65).
Mean (SD)/No (%)
Age (years)57.8 ± 9.3
Sex (male)49 (75%)
Body mass index (kg/m2)29.2 ± 4.4
Comorbidity
-
Atrial fibrillation
-
COPD
  • Mild
  • Moderate
  • Severe
  • Very severe

12 (18%)
18 (28%)
8 (44%)
9 (50%)
1 (6%)
0 (0%)
Functional class
-
NYHA class I
-
NYHA class II
-
NYHA class III
-
NYHA class IV

13 (20%)
41 (63%)
11 (17%)
0 (0%)
Cause of HFrEF
-
Ischemic
-
Idiopathic
-
Hereditary
-
Other

28 (44%)
27 (42%)
6 (9%)
4 (5%)
LVEF (%)29.5 ± 8.6
Laboratory values
-
Hemoglobin (g/dL)
-
Creatinine (mg/dL)
-
Glomerular filtration rate (mL/min/1.73 m2)

14.05 ± 1.78
1.19 ± 0.8
71.6 ± 19.09
Spirometry (mL/% theoretical)
-
FEV1
-
FVC
-
FEV1/FVC ratio

2701 ± 757 (84 ± 16%)
3762 ± 1020 (90 ± 16%)
71 ± 7%
Chronic treatment
-
Beta-blocker
-
ACE-I
-
ARB
-
Mineralocorticoid receptor antagonist
-
Angiotensin receptor-neprilysin inhibitor
-
Loop diuretic
-
Thiazides
-
Ivabradine
-
Digoxin
-
Amiodarone

63 (97%)
37 (57%)
27 (41%)
37 (57%)
22 (34%)
45 (69%)
2 (3%)
7 (11%)
1 (2%)
4 (6%)
Implantable cardioverter defibrillator
-
Single chamber
-
Cardiac resynchronization therapy
34 (52%)
11 (32%)
23 (68%)
COPD: chronic obstructive pulmonary disease; NYHA: New York Heart Association; HFrEF: heart failure with reduced left ventricular ejection fraction; LVEF: left ventricular ejection fraction; FEV1: maximum expiratory volume in the first second; FVC: forced vital capacity; ACE-I: angiotensin converting enzyme inhibitor; ARB: angiotensin AT1-receptor blocker.
Table 2. Cardiopulmonary exercise testing parameters.
Table 2. Cardiopulmonary exercise testing parameters.
CPET VariableTreadmillCycle Ergometerp Value
Test Duration (minutes)10.5 ± 2.710.2 ± 3.1NS
Reached VT (%)93.8%76.9%p < 0.05
RQ Max1.04 ± 0.051.03 ± 0.06NS
HR at Rest (bpm)69.6 ± 10.968.8 ± 11.0NS
HR at Maximum Effort (bpm)117.3 ± 15.7107.5 ± 15.2p < 0.000
HR Recovery Index (bpm)22.4 ± 12.816.4 ± 8.8p < 0.000
SBP at Rest (mmHg)123.3 ± 21.6125.3 ± 21.8NS
SBP at the End of Exercise (mmHg)158.7 ± 33.5161.4 ± 30.9NS
DBP at Rest (mmHg)75.8 ± 10.878.9 ± 12.2p < 0.05
DBP at the End of Exercise (mmHg)81.5 ± 16.687.4 ± 16.2p < 0.000
Initial O2 Saturation (%)97.0 ± 1.397.2 ± 1.2NS
Final O2 Saturation (%)96.4 ± 1.897.2 ± 1.4p < 0.000
Resting VO2 (mL/min)412.7 ± 162.2416.6 ± 166.1NS
Peak VO2 (mL/min)1734.9 ± 549.91390.5 ± 427.0p < 0.000
Peak VO2/kg (mL/min/kg)21.0 ± 5.116.9 ± 4.1p < 0.000
VO2 at VT (mL/min)1612.5 ± 382.51274.0 ± 361.8p < 0.000
VCO2 at VT (mL/min)1587.7 ± 376.21259.0± 354.3p < 0.000
O2 pulse at VT (mL/bpm)14.6 ± 3.612.5 ± 3.3p < 0.000
VE/VCO2 Slope32.2 ± 7.933.9 ± 8.8p < 0.05
VE Max (L/min)54.7 ± 16.345.8 ± 11.4p < 0.000
RR Max (rpm)30.5 ± 5.627.3 ± 5.0p < 0.000
EqO2 at VT35.6 ± 4.937.0 ± 5.5p < 0.05
EQCO2 at VT36.3 ± 5.037.4 ± 5.4p < 0.05
PETCO2 at Rest (mmHg)32.0 ± 4.432.8 ± 4.9NS
PETCO2 at VT (mmHg)36.2 ± 4.236.1 ± 4.5NS
ΔPETCO2(mmHg)3.8 ± 4.02.3 ± 4.7p < 0.05
BR at Maximum Effort (%)28.4 ± 17.141.1 ± 15.2p < 0.000
Exercise Oscillatory Ventilation(%)29.636.5NS
Final Borg Dyspnea (1–10)5.4 ± 2.43.7 ± 2.3p < 0.000
Final Borg Lower Limbs (1–10)3.8 ± 3.14.8 ± 2.4p < 0.05
CPET: Cardiopulmonary exercise test; VT: ventilatory threshold; RQ: respiratory quotient; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; VO2: oxygen consumption; VCO2: CO2 production; VE: ventilation; RR: respiratory rate; EqO2: oxygen equivalent; EqCO2: carbon dioxide equivalent; PETCO2: partial pressure end-tidal carbon dioxide; ΔPETCO2: PETCO2 increase from start of test to VT; BR: breathing reserve; NS: not significant.
Table 3. VO2 variation during CPET.
Table 3. VO2 variation during CPET.
TreadmillCycle Ergometerp-Value
VO2 at rest412.7 ± 162.2416.6 ± 166.1NS
VT VO21612.5 ± 382.51274.0 ± 361.8<0.000
Peak VO21734.9 ± 549.91390.5 ± 427.0<0.000
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Herrero Huertas, J.; García Clemente, M.; Díaz Molina, B.; Lambert Rodríguez, J.L.; Íscar Urrutia, M. Heart Failure with Reduced Ejection Fraction and Prognostic Scales: The Impact of Exercise Modality in Cardiopulmonary Exercise Tests. J. Clin. Med. 2022, 11, 3122. https://doi.org/10.3390/jcm11113122

AMA Style

Herrero Huertas J, García Clemente M, Díaz Molina B, Lambert Rodríguez JL, Íscar Urrutia M. Heart Failure with Reduced Ejection Fraction and Prognostic Scales: The Impact of Exercise Modality in Cardiopulmonary Exercise Tests. Journal of Clinical Medicine. 2022; 11(11):3122. https://doi.org/10.3390/jcm11113122

Chicago/Turabian Style

Herrero Huertas, Julia, Marta García Clemente, Beatriz Díaz Molina, José Luis Lambert Rodríguez, and Marta Íscar Urrutia. 2022. "Heart Failure with Reduced Ejection Fraction and Prognostic Scales: The Impact of Exercise Modality in Cardiopulmonary Exercise Tests" Journal of Clinical Medicine 11, no. 11: 3122. https://doi.org/10.3390/jcm11113122

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop